However, 2 of these patients with EHPVO presented as re-bleeders after previous variceal sclerosis and were managed by additional sclerotherapy sessions.
The study cohort had a nearly even distribution of EHPVO and intrahepatic disease as a cause of varices, allowing us to compare modes of sclerotherapy and determine if outcome was influenced by underlying aetiology.
Early portoenterostomy and LT availability have contributed to a higher incidence of children requiring sclerotherapy for intrahepatic portal hypertension compared with the Hill and Bowie (8) study where most patients had EHPVO.
In this study, more children with intrahepatic disease than EHPVO bled within the first 2 years of life.
In contrast to other studies, (2,9,10) the success rate with sclerotherapy alone on EHPVO was 20.
There is, to date, no consensus on EHPVO management.
8% of EHPVO and 30% of intrahepatic disease patients had gastric varices.
4% with EHPVO presented with variceal bleeding were aged <3 years, sclerotherapy and octreotide have to be used as a first treatment option and subsequently sclerotherapy alone in controlling variceal bleeding while awaiting LT or an appropriate shunt procedure in EHPVO.